340 related articles for article (PubMed ID: 1682541)
1. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.
Bjune G; Høiby EA; Grønnesby JK; Arnesen O; Fredriksen JH; Halstensen A; Holten E; Lindbak AK; Nøkleby H; Rosenqvist E
Lancet; 1991 Nov; 338(8775):1093-6. PubMed ID: 1682541
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
Noronha CP; Struchiner CJ; Halloran ME
Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
[TBL] [Abstract][Full Text] [Related]
3. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.
Bjune G; Grønnesby JK; Høiby EA; Closs O; Nøkleby H
NIPH Ann; 1991 Dec; 14(2):125-30; discussion 130-2. PubMed ID: 1812425
[TBL] [Abstract][Full Text] [Related]
4. Status of a group B Neisseria meningitidis vaccine.
Frasch CE
Eur J Clin Microbiol; 1985 Dec; 4(6):533-6. PubMed ID: 3937731
[No Abstract] [Full Text] [Related]
5. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
Jennings HJ
Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
[No Abstract] [Full Text] [Related]
6. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.
Tappero JW; Lagos R; Ballesteros AM; Plikaytis B; Williams D; Dykes J; Gheesling LL; Carlone GM; Høiby EA; Holst J; Nøkleby H; Rosenqvist E; Sierra G; Campa C; Sotolongo F; Vega J; Garcia J; Herrera P; Poolman JT; Perkins BA
JAMA; 1999 Apr; 281(16):1520-7. PubMed ID: 10227322
[TBL] [Abstract][Full Text] [Related]
7. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.
Fischer M; Carlone GM; Holst J; Williams D; Stephens DS; Perkins BA
Vaccine; 1999 May; 17(19):2377-83. PubMed ID: 10392619
[TBL] [Abstract][Full Text] [Related]
8. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.
Holst J; Feiring B; Fuglesang JE; Høiby EA; Nøkleby H; Aaberge IS; Rosenqvist E
Vaccine; 2003 Jan; 21(7-8):734-7. PubMed ID: 12531351
[TBL] [Abstract][Full Text] [Related]
9. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
[TBL] [Abstract][Full Text] [Related]
10. Control of meningococcal infection in the African meningitis belt by selective vaccination.
Greenwood BM; Wali SS
Lancet; 1980 Apr; 1(8171):729-32. PubMed ID: 6103155
[TBL] [Abstract][Full Text] [Related]
11. Who should be given meningococcal vaccine?
Lancet; 1978 Dec; 2(8101):1185-6. PubMed ID: 82146
[No Abstract] [Full Text] [Related]
12. Meningococcal group B vaccine trial in Norway 1981--1982. Preliminary report of results available November 1982.
Frøholm LO; Berdal BP; Bøvre K; Gaustad P; Harboe A; Holten E; Høiby EA; Lystad A; Omland T; Frasch CE
NIPH Ann; 1983 Dec; 6(2):133-8. PubMed ID: 6427703
[TBL] [Abstract][Full Text] [Related]
13. Effect of group-A meningococcal vaccine in army recruits in Finland.
Mäkelä PH; Käyhty H; Weckström P; Sivonen A; Renkonen OV
Lancet; 1975 Nov; 2(7941):883-6. PubMed ID: 53370
[TBL] [Abstract][Full Text] [Related]
14. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
[TBL] [Abstract][Full Text] [Related]
15. Control of epidemic meningococcal meningitis by mass vaccination. I. Further epidemiological evaluation of groups A and C vaccines in northern Nigeria.
Mohammed I; Obineche EN; Onyemelukwe GC; Zaruba K
J Infect; 1984 Sep; 9(2):190-6. PubMed ID: 6438244
[TBL] [Abstract][Full Text] [Related]
16. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
de Moraes JC; Perkins BA; Camargo MC; Hidalgo NT; Barbosa HA; Sacchi CT; Landgraf IM; Gattas VL; Vasconcelos Hde G
Lancet; 1992 Oct; 340(8827):1074-8. PubMed ID: 1357461
[TBL] [Abstract][Full Text] [Related]
17. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A.
Erwa HH; Haseeb MA; Idris AA; Lapeyssonnie L; Sanborn WR; Sippel JE
Bull World Health Organ; 1973; 49(3):301-5. PubMed ID: 4211056
[TBL] [Abstract][Full Text] [Related]
18. Control of epidemic meningococcal meningitis by mass vaccination.
Mohammed I; Zaruba K
Lancet; 1981 Jul; 2(8237):80-2. PubMed ID: 6113451
[No Abstract] [Full Text] [Related]
19. [Vaccination Project-88. New Norwegian vaccine against type B meningitis--what happened?].
Rød KA
Fag Tidsskr Sykepleien; 1990 Jan; 78(1):27-31. PubMed ID: 2109367
[No Abstract] [Full Text] [Related]
20. Trial of a serogroup A meningococcus polysaccharide vaccine in Nigeria.
Sanborn WR; Bencić Z; Cvjetanović B; Gotschlich EC; Pollock TM; Sippel JE
Prog Immunobiol Stand; 1971; 5():497-505. PubMed ID: 4633977
[No Abstract] [Full Text] [Related]
[Next] [New Search]
